| Business Summary | | EDAP
TMS
S.A.
develops,
produces,
markets
and
distributes
a
portfolio
of
minimally
invasive
medical
devices
primarily
for
the
treatment
of
urological
diseases.
The
Company
currently
produces
and
markets
devices
for
the
treatment
of
benign
prostate
hyperplasia
(BPH),
prostate
cancer
and
urinary
tract
stones.
The
Company
is
also
developing
products
for
the
minimally
invasive
destruction
of
certain
types
of
tumors.
The
Company's
product
portfolio
includes
Prostratron,
a
medical
device
using
transurethral
microwave
thermotherapy
(TUMT);
three
models
of
lithotripters,
the
LT02,
the
SONOLITH
4000
and
the
SONOLITH
Praktis,
and
Ablatherm,
a
medical
device
based
on
high-intensity
focused
ultrasound
(HIFU)
technology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | EDAP
TMS
S.A.
develops,
produces,
markets
and
distributes
a
portfolio
of
minimally
invasive
medical
devices,
primarily
for
the
treatment
of
urological
diseases.
For
the
six
months
ended
6/30/01,
total
revenues
rose
4%
to
EUR12M.
Net
income
totaled
EUR3.3
million
vs.
a
loss
of
EUR2.3
million.
Revenues
reflect
increased
sales
of
medical
equipment
due
to
strong
sales
in
the
lithotripsy
business.
Earnings
also
reflect
increased
currency
gains
and
other
income. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Philippe Chauveau | Chairman | Eric Simon, 39 | Pres,
CEO | Ian Vawter | CFO | Antoine Tetard, 35 | Pres,
United States Operations and Japanese Operations | Hugo Verpeet, 49 | Pres
and Gen. Mang. of TMS |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|